Alfresa Holdings Corporation has decided to include its non-consolidated subsidiary ArkMS Co., Ltd. (Headquarters: Toshima-ku, Tokyo; President: Hitoshi Mizuo; hereinafter 'ArkMS'), which operates a CRO (Contract Research Organization) business, within its scope of consolidation.
1. Reason for the Change in Subsidiary In its medium-to-long-term vision toward FY2032 and the '25-27 Medium-Term Management Plan Vision2032 Stage 2,' the Alfresa Group has positioned the 'Total Supply Chain Service (TSCS)' as a core business strategy. TSCS provides an integrated service across the entire value chain, from drug introduction, development, and manufacturing to logistics, sales, Post-Marketing Surveillance (PMS), and the last mile.
Alfresa acquired all shares of ArkMS, which was established through a company split by Intage Healthcare Co., Ltd., and made it a wholly-owned subsidiary in September 2024. As ArkMS will play an increasingly significant role in supporting pharmaceutical development within TSCS, its qualitative importance has increased. Therefore, the company decided to include ArkMS in its consolidated accounts starting from the first quarter of the fiscal year ending March 2027.
*1 CRO: Contract Research Organization. A specialized organization that supports a series of tasks related to clinical trials conducted by pharmaceutical companies and research institutions. *2 Reference: Announcement of 'Alfresa Group Medium-to-Long-Term Vision' on May 15, 2023. *3 Reference: Announcement of '25-27 Medium-Term Management Plan Vision2032 Stage 2' on May 15, 2025. *4 PMS: Post-Marketing Surveillance. Surveys conducted after pharmaceuticals or medical devices are marketed to ensure quality, efficacy, and safety. *5 TSCS: Refers to the establishment of a seamless supply chain by organically integrating various functions across the Alfresa Group to provide services from introduction/development to logistics/sales and PMS.
FACT BOX
- Source: PR TIMES
- Category: News